Differentially expressed microRNAs in Huh-7 cells expressing HCV core genotypes 3a or 1b: Potential functions and downstream pathways

International Journal of Molecular Medicine

Volumn 30, Issue 2, 2012, Pages 374-382

  Gu, Yu ^a   Xu, Yuqiao ^a   Jiang, Lina ^a   Cao, Xiangmei ^a   Liu, Fang ^a   Li, Hang ^a   Zhang, Liying ^a   Li, Zengshan ^a   Li, Jing ^a   Ye, Jing ^a   Li, Qing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gene ontology; Hepatitis C virus; Microarray; MicroRNA

Indexed keywords

MICRORNA;

ARTICLE; CELL GROWTH; CELL METABOLISM; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; VIRUS CORE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LIVER NEOPLASMS; MICRORNAS; SIGNAL TRANSDUCTION; VIRAL CORE PROTEINS;

EID: 84863539854     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.991     Document Type: Article

References (46)

1. Khaliq S, Jahan S and Pervaiz A: Sequence variability of HCV core region: important predictors of HCV induced pathogenesis and viral production. Infect Genet Evol 11: 543-556, 2011.
2. Arrese M, Riquelme A and Soza A: Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol (Suppl 9): S112-S118, 2010.
3. Ripoli M and Pazienza V: Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 9: 747-759, 2011.
4. Pazienza V, Clement S, Pugnale P, et al: Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. Liver Int 29: 661-669, 2009.
5. Wu L and Belasco JG: Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 29: 1-7, 2008.
6. Peng X, Li Y, Walters KA, et al: Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 10: 373, 2009.
7. Steuerwald NM, Parsons JC, Bennett K, Bates TC and Bonkovsky HL: Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver Int 30: 1490-1504, 2010.
8. Jopling CL, Yi M, Lancaster AM, Lemon SM and Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309: 1577-1581, 2005.
9. Abid K, Pazienza V, de Gottardi A, et al: An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 42: 744-751, 2005.
10. Jin X, Chen YP, Kong M, Zheng L, Yang YD and Li YM: Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol 27: 331-340, 2011.
11. Huang da W, Sherman BT, Tan Q, et al: DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: W169-W175, 2007.
12. Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509, 1957.
13. Hoofnagle JH: Hepatitis C: the clinical spectrum of disease. Hepatology 26 (Suppl 1): S15-S20, 1997.
14. Klibanov OM, Williams SH, Smith LS, Olin JL and Vickery SB: Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy 31: 951-974, 2011.
15. Jopling C: Liver-specific microRNA-122: Biogenesis and function. RNA Biol 9: 137-142, 2012.
16. Pedersen IM, Cheng G, Wieland S, et al: Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449: 919-922, 2007.
17. Fried MW, Shiffman M, Sterling RK, et al: A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 95: 3225-3229, 2000.
18. Chevaliez S and Asselah T: Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol 35 (Suppl 1): S31-S41, 2011.
19. Camma C, Bruno S, Di Marco V, et al: Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43: 64-71, 2006.
20. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E and Mondelli MU: Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46: 1350-1356, 2007.
21. Lin J, Huang S, Wu S, et al: MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis 32: 1641-1647, 2011.
22. Sengupta S, Nie J, Wagner RJ, Yang C, Stewart R and Thomson JA: MicroRNA 92b controls the G1/S checkpoint gene p57 in human embryonic stem cells. Stem Cells 27: 1524-1528, 2009.
23. Yi C, Wang Q, Wang L, et al: miR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene: Jan 16, 2012 (Epub ahead of print).
24. Yoon S, Choi YC, Lee S, Jeong Y, Yoon J and Baek K: Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 584: 4048-4052, 2010.
25. Afanasyeva EA, Mestdagh P, Kumps C, et al: MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 18: 974-984, 2011.
26. Feng S, Cong S, Zhang X, et al: MicroRNA-192 targeting retino blastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 39: 6669-6678, 2011.
27. Wang Y and Lee CG: Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics 3: 235-243, 2011.
28. Lee YM, Lee JY, Ho CC, et al: MicroRNA 34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res 13: R116, 2011.
29. Huang Z, Huang S, Wang Q, et al: MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 71: 2582-2589, 2011.
30. Zaragosi LE, Wdziekonski B, Brigand KL, et al: Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogen esis. Genome Biol 12: R64, 2011.
31. Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005.
32. Piodi A, Chouteau P, Lerat H, Hezode C and Pawlotsky JM: Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relation ship with steatosis. Hepatology 48: 16-27, 2008.
33. Jackel-Cram C, Babiuk LA and Liu Q: Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 46: 999-1008, 2007.
34. Soupene E and Kuypers FA: Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233: 507-521, 2008.
35. Burg JS and Espenshade PJ: Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res 50: 403-410, 2011.
36. Onoyama I, Suzuki A, Matsumoto A, et al: Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest 121: 342-354, 2010.
37. Loewen CJ and Levine TP: Cholesterol homeostasis: not until the SCAP lady INSIGs. Curr Biol 12: R779-R781, 2002.
38. Martin S and Parton RG: Caveolin, cholesterol, and lipid bodies. Semin Cell Dev Biol 16: 163-174, 2005.
39. Klappe K, Hummel I, Hoekstra D and Kok JW: Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 161: 57-64, 2009.
40. Agellon LB, Drozdowski L, Li L, et al: Loss of intestinal fatty acid binding protein increases the susceptibility of male mice to high fat diet-induced fatty liver. Biochim Biophys Acta 1771: 1283-1288, 2007.
41. Schmitt E, Ballou MA, Correa MN, DePeters EJ, Drackley JK and Loor JJ: Dietary lipid during the transition period to manipulate subcutaneous adipose tissue peroxisome proliferator-activated receptor-gamma co-regulator and target gene expression. J Dairy Sci 94: 5913-5925, 2011.
42. Colak Y, Ozturk O, Senates E, et al: SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 17: HY5-HY9, 2011.
43. Glasgow E and Mishra L: Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer 15: 59-72, 2008.
44. Thorgeirsson SS, Teramoto T and Factor VM: Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 18: 115-122, 1998.
45. Breuhahn K and Schirmacher P: Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 14: 1690-1698, 2008.
46. Jahan S, Ashfaq UA, Khaliq S, Samreen B and Afzal N: Dual behavior of HCV core gene in regulation of apoptosis is important in progression of HCC. Infect Genet Evol 12: 236-239, 2012.